Skip to content

Combined and Separate Effects of Cannabis and Tobacco: Psychomotor, Subjective and Physiological Outcomes

Combined and Separate Effects of Cannabis and Tobacco: Psychomotor, Subjective and Physiological Outcomes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05526196
Acronym
CASE-CT
Enrollment
60
Registered
2022-09-02
Start date
2024-10-07
Completion date
2027-03-01
Last updated
2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Driving Under the Influence

Brief summary

Co-administration of cannabis and tobacco is a common practice, but there is little experimental evidence aimed at understanding the reasons for this prevalence. Some preliminary evidence suggests that tobacco may actually counteract the cognitive-impairing effects of cannabis, and may also increase the subjective ('liking') effects of cannabis, but results are inconclusive. Further, there are no studies into the effects of tobacco on other cannabis-related harms such as driving, or on the ability of tobacco to alter the blood levels of THC, the chemical responsible for the psychoactive properties of cannabis. The purpose of the present study will be to evaluate the effects of tobacco, cannabis or combinations of tobacco and cannabis on driving, cognition, subjective effects and blood THC. Driving will be assessed using a state-of-the-art driving simulator that allows for the safe and objective measurement of the effects of intoxicating substances on driving. Participants will be regular users of cannabis and will be invited to the lab for four counterbalanced test sessions. In these test sessions they will drive the simulator and undergo cognitive tests before and after smoking: 1) cannabis; 2) tobacco; 3) cannabis + tobacco; or 4) placebo. Outcomes will be measured at several time points after smoking the product. Participants will also give blood for determination of levels of THC, and will complete subjective effects questionnaires both before and after smoking the cigarette. This study will be one of the first experimental laboratory studies of the reasons behind co-administration of tobacco and cannabis.

Interventions

DRUGCannabis

Dried flower cannabis cigarette with 22% THC

DRUGTobacco

Dried flower cigarette with active nicotine

DRUGCannabis tobacco

Dried flower cigarette with active nicotine and cannabis

DRUGPlacebo

Dried flower cigarette with both placebo tobacco and cannabis

Sponsors

Centre for Addiction and Mental Health
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* • Adults aged 19 years to 45 years (to control for the effects of age on cognition) * Smoke or vape cannabis at least once a month but no more than 4 times a week (to avoid enrolling people with cannabis use disorder who may experience withdrawal when asked to abstain from cannabis) * Experience with smoked cannabis in the past year * Report use of at least 100 cigarettes in their lifetime to ensure familiarity with the tobacco used in the present study * Use of any nicotine (smoked, vaped, etc) in the past year * G2 or full G driver's licence for at least a year * Willing to abstain from alcohol and other drugs (other than drugs required for treatment of a medical condition) for 48 hours prior to study session * Normal heart rate and blood pressure as determined by the QI (because cannabis and tobacco increase heart rate) * Normal ECG (because cannabis and tobacco increase heart rate) * Willing to abstain from cannabis for 72 hours prior to the test session and from smoking tobacco for 12 hours * Willing to use an accepted form of contraception during the study (both males and females) * Past lifetime experience with co-use of cannabis or tobacco (either simultaneous or concurrent) * Provides written and informed consent

Exclusion criteria

* • Use of psychoactive medications or drugs * Current alcohol or other substance use disorder, including cannabis (as assessed with the SCID) * Current or past nicotine dependence (to avoid precipitating a relapse) * Withdrawal symptoms as assessed with the Marijuana Withdrawal Checklist \[57, 58\] * A score of less than 10 on the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) \[59\] * Family history of schizophrenia or psychosis (to avoid giving cannabis to anyone with a predisposition to psychosis) * Respiratory illnesses (due to the smoked route of administration in this study) * Any serious medical condition precluding participation as judged by the responsible study physician * Pregnancy or breastfeeding * Negative urine screen for cannabis at eligibility assessment (to ensure experience with cannabis) * Neurological disorders that may affect cognitive function * Treatment-seeking for tobacco or cannabis use * Use of more than 5 cigarettes a day (to avoid confound of the effects of chronic smoking on measures) * Concomitant therapy with sedative-hypnotics or other psychoactive drugs (counter-indicated with cannabis)

Design outcomes

Primary

MeasureTime frameDescription
Standard deviation of lateral positionbaselinecar 'weaving'

Secondary

MeasureTime frameDescription
Verbal free recallbaselineTest of memory
Addiction Research Centre InventorybaselineTest of mood with 53 true-false questions that are summed to produce a measure of the intensity of mood, with higher scores reflecting greater mood
Profile of Mood StatesbaselineTest of mood with 76 items with a five point scale that are summed to produce a measure of the intensity of mood, with higher scores indicating more agreemen
Visual Analog Scalebaselinetest of mood on a scale from 0 to 100, with greater number indicating more agreement
SpeedbaselineSpeed (in km) of the car
Reaction timebaselineTime to hit the brake after introduction of an obstacle
Collisionsbaselinenumber of times the car hit an obstacle
Concentration of THC (ng/ml)BaselinePsychoactive component of cannabis
Useful Field of View Processing SpeedbaselineMean threshold for discriminating stimuli presented in central vision
Useful Field of View Divided attentionbaselineMean threshold for discriminating stimuli presented in central vision, with a concurrent perpheral target task
Trail making taskbaselineCognitive assessment
Useful Field of View Selective attentionbaselineMean threshold for divided attention but with distractors

Countries

Canada

Contacts

CONTACTPatricia Di Ciano
patricia.diciano@camh.ca416-535-8501

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026